Global Peptide Cancer Vaccine Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Description
Market Overview
According to DIResearch's in-depth investigation and research, the global Peptide Cancer Vaccine market size will reach 969.97 Million USD in 2025 and is projected to reach 2,603.79 Million USD by 2032, with a CAGR of 15.15% (2025-2032). Notably, the China Peptide Cancer Vaccine market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
A peptide cancer vaccine is an immunotherapeutic approach used in the field of cancer treatment and prevention. It is designed to stimulate the body's immune system to recognize and attack cancer cells by targeting specific proteins or peptides that are unique to those cancer cells. The vaccine typically contains a selected peptide or a combination of peptides derived from tumor-associated antigens, which are substances present on cancer cells but not on normal healthy cells. By introducing these peptides into the patient's body, the vaccine aims to trigger an immune response that targets and destroys cancer cells while sparing healthy tissues. Peptide cancer vaccines are considered a personalized and targeted therapy, as they can be customized to a patient's specific cancer type, and they hold promise for various cancer treatments, including melanoma and certain types of breast, prostate, and lung cancers. Clinical research and development in this field continue to explore the potential of peptide cancer vaccines as a complementary approach to traditional cancer treatments like surgery, chemotherapy, and radiation therapy.
The major global manufacturers of Peptide Cancer Vaccine include Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Imugene, Sellas, Generex Biotechnology, VAXON Biotech, OncoTherapy Science, ISA Pharmaceuticals, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Peptide Cancer Vaccine. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Peptide Cancer Vaccine market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Peptide Cancer Vaccine market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Peptide Cancer Vaccine industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Manufacturers of Peptide Cancer Vaccine Include:
Boston Biomedical
Ultimovacs
BrightPath Biotherapeutics
TapImmune
Immatics
Imugene
Sellas
Generex Biotechnology
VAXON Biotech
OncoTherapy Science
ISA Pharmaceuticals
Peptide Cancer Vaccine Product Segment Include:
ITK-1
GRN-1201
TPIV200
TPIV110
UV1
Galinpepimut-S
TARP 27-35
HER-Vaxx
Vx-001
Others
Peptide Cancer Vaccine Product Application Include:
Breast Cancer
Lung Cancer
Melanoma
Prostate Cancer
Others
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Peptide Cancer Vaccine Industry PESTEL Analysis
Chapter 3: Global Peptide Cancer Vaccine Industry Porter's Five Forces Analysis
Chapter 4: Global Peptide Cancer Vaccine Major Regional Market Size (Sales, Revenue, Price) and Forecast Analysis
Chapter 5: Global Peptide Cancer Vaccine Competitive Analysis of Key Manufacturers (Sales, Revenue, Market Share, Price, Regional Distribution and Industry Concentration)
Chapter 6: Global Peptide Cancer Vaccine Sales, Revenue, Price and Forecast by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Sales, Revenue, Price and Gross Margin)
Chapter 8: Industrial Chain Analysis, Peptide Cancer Vaccine Different Application Market Analysis (Sales and Revenue), Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
According to DIResearch's in-depth investigation and research, the global Peptide Cancer Vaccine market size will reach 969.97 Million USD in 2025 and is projected to reach 2,603.79 Million USD by 2032, with a CAGR of 15.15% (2025-2032). Notably, the China Peptide Cancer Vaccine market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
A peptide cancer vaccine is an immunotherapeutic approach used in the field of cancer treatment and prevention. It is designed to stimulate the body's immune system to recognize and attack cancer cells by targeting specific proteins or peptides that are unique to those cancer cells. The vaccine typically contains a selected peptide or a combination of peptides derived from tumor-associated antigens, which are substances present on cancer cells but not on normal healthy cells. By introducing these peptides into the patient's body, the vaccine aims to trigger an immune response that targets and destroys cancer cells while sparing healthy tissues. Peptide cancer vaccines are considered a personalized and targeted therapy, as they can be customized to a patient's specific cancer type, and they hold promise for various cancer treatments, including melanoma and certain types of breast, prostate, and lung cancers. Clinical research and development in this field continue to explore the potential of peptide cancer vaccines as a complementary approach to traditional cancer treatments like surgery, chemotherapy, and radiation therapy.
The major global manufacturers of Peptide Cancer Vaccine include Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Imugene, Sellas, Generex Biotechnology, VAXON Biotech, OncoTherapy Science, ISA Pharmaceuticals, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Peptide Cancer Vaccine. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Peptide Cancer Vaccine market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Peptide Cancer Vaccine market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Peptide Cancer Vaccine industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Manufacturers of Peptide Cancer Vaccine Include:
Boston Biomedical
Ultimovacs
BrightPath Biotherapeutics
TapImmune
Immatics
Imugene
Sellas
Generex Biotechnology
VAXON Biotech
OncoTherapy Science
ISA Pharmaceuticals
Peptide Cancer Vaccine Product Segment Include:
ITK-1
GRN-1201
TPIV200
TPIV110
UV1
Galinpepimut-S
TARP 27-35
HER-Vaxx
Vx-001
Others
Peptide Cancer Vaccine Product Application Include:
Breast Cancer
Lung Cancer
Melanoma
Prostate Cancer
Others
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Peptide Cancer Vaccine Industry PESTEL Analysis
Chapter 3: Global Peptide Cancer Vaccine Industry Porter's Five Forces Analysis
Chapter 4: Global Peptide Cancer Vaccine Major Regional Market Size (Sales, Revenue, Price) and Forecast Analysis
Chapter 5: Global Peptide Cancer Vaccine Competitive Analysis of Key Manufacturers (Sales, Revenue, Market Share, Price, Regional Distribution and Industry Concentration)
Chapter 6: Global Peptide Cancer Vaccine Sales, Revenue, Price and Forecast by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Sales, Revenue, Price and Gross Margin)
Chapter 8: Industrial Chain Analysis, Peptide Cancer Vaccine Different Application Market Analysis (Sales and Revenue), Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
Table of Contents
165 Pages
- 1 Peptide Cancer Vaccine Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 Peptide Cancer Vaccine Product by Type
- 1.2.1 ITK-1
- 1.2.2 GRN-1201
- 1.2.3 TPIV200
- 1.2.4 TPIV110
- 1.2.5 UV1
- 1.2.6 Galinpepimut-S
- 1.2.7 TARP 27-35
- 1.2.8 HER-Vaxx
- 1.2.9 Vx-001
- 1.2.10 Others
- 1.3 Peptide Cancer Vaccine Product by Application
- 1.3.1 Breast Cancer
- 1.3.2 Lung Cancer
- 1.3.3 Melanoma
- 1.3.4 Prostate Cancer
- 1.3.5 Others
- 1.4 Global Peptide Cancer Vaccine Market Revenue and Sales Analysis
- 1.4.1 Global Peptide Cancer Vaccine Revenue Market Size Analysis (2020-2032)
- 1.4.2 Global Peptide Cancer Vaccine Sales Market Size Analysis (2020-2032)
- 1.4.3 Global Peptide Cancer Vaccine Market Sales Price Trend Analysis (2020-2032)
- 1.5 Peptide Cancer Vaccine Market Development Status and Trends
- 1.5.1 Peptide Cancer Vaccine Industry Development Status Analysis
- 1.5.2 Peptide Cancer Vaccine Industry Development Trends Analysis
- 2 Peptide Cancer Vaccine Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 Peptide Cancer Vaccine Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global Peptide Cancer Vaccine Market Analysis by Country
- 4.1 Global Peptide Cancer Vaccine Market Size Analysis by Country: 2024 VS 2025 VS 2032
- 4.1.1 Global Peptide Cancer Vaccine Revenue and Market Share by Country (2020-2025)
- 4.1.2 Global Peptide Cancer Vaccine Revenue and Market Share Forecast by Country (2026-2032)
- 4.2 Global Peptide Cancer Vaccine Sales Analysis by Country: 2024 VS 2025 VS 2032
- 4.2.1 Global Peptide Cancer Vaccine Sales and Market Share by Country (2020-2025)
- 4.2.2 Global Peptide Cancer Vaccine Sales and Market Share Forecast by Country (2026-2032)
- 4.3 United States Peptide Cancer Vaccine Market Sales, Revenue and Growth Rate (2020-2032)
- 4.4 Germany Peptide Cancer Vaccine Market Sales, Revenue and Growth Rate (2020-2032)
- 4.5 Japan Peptide Cancer Vaccine Market Sales, Revenue and Growth Rate (2020-2032)
- 4.6 China Peptide Cancer Vaccine Market Sales, Revenue and Growth Rate (2020-2032)
- 4.7 France Peptide Cancer Vaccine Market Sales, Revenue and Growth Rate (2020-2032)
- 4.8 U.K. Peptide Cancer Vaccine Market Sales, Revenue and Growth Rate (2020-2032)
- 4.9 South Korea Peptide Cancer Vaccine Market Sales, Revenue and Growth Rate (2020-2032)
- 4.10 Canada Peptide Cancer Vaccine Market Sales, Revenue and Growth Rate (2020-2032)
- 4.11 Italy Peptide Cancer Vaccine Market Sales, Revenue and Growth Rate (2020-2032)
- 4.12 Russia Peptide Cancer Vaccine Market Sales, Revenue and Growth Rate (2020-2032)
- 4.13 Mexico Peptide Cancer Vaccine Market Sales, Revenue and Growth Rate (2020-2032)
- 4.14 Brazil Peptide Cancer Vaccine Market Sales, Revenue and Growth Rate (2020-2032)
- 4.15 India Peptide Cancer Vaccine Market Sales, Revenue and Growth Rate (2020-2032)
- 4.16 Vietnam Peptide Cancer Vaccine Market Sales, Revenue and Growth Rate (2020-2032)
- 4.17 Thailand Peptide Cancer Vaccine Market Sales, Revenue and Growth Rate (2020-2032)
- 4.18 South Africa Peptide Cancer Vaccine Market Sales, Revenue and Growth Rate (2020-2032)
- 5 Competition by Manufacturers
- 5.1 Global Peptide Cancer Vaccine Market Sales, Revenue and Sales Price by Key Manufacturers (2021-2025)
- 5.1.1 Global Peptide Cancer Vaccine Market Sales by Key Manufacturers (2021-2025)
- 5.1.2 Global Peptide Cancer Vaccine Market Revenue by Key Manufacturers (2021-2025)
- 5.1.3 Global Peptide Cancer Vaccine Average Sales Price by Manufacturers (2021-2025)
- 5.2 Peptide Cancer Vaccine Competitive Landscape Analysis and Market Dynamic
- 5.2.1 Peptide Cancer Vaccine Competitive Landscape Analysis
- 5.2.2 Global Key Manufacturers Headquarter and Key Area Sales
- 5.2.3 Market Dynamic
- 6 Peptide Cancer Vaccine Market Analysis by Type
- 6.1 Global Peptide Cancer Vaccine Market Revenue Analysis by Type
- 6.1.1 Global Peptide Cancer Vaccine Market Size Analysis by Type: 2024 & 2025 & 2032
- 6.1.2 Global Peptide Cancer Vaccine Revenue and Forecast Analysis by Type (2020-2032)
- 6.2 Global Peptide Cancer Vaccine Market Sales and Forecast Analysis by Type (2020-2032)
- 6.3 Global Peptide Cancer Vaccine Sales Price Trend Analysis by Type (2020-2032)
- 7 Key Companies Analysis
- 7.1 Boston Biomedical
- 7.1.1 Boston Biomedical Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.1.2 Boston Biomedical Peptide Cancer Vaccine Product Portfolio
- 7.1.3 Boston Biomedical Peptide Cancer Vaccine Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.2 Ultimovacs
- 7.2.1 Ultimovacs Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.2.2 Ultimovacs Peptide Cancer Vaccine Product Portfolio
- 7.2.3 Ultimovacs Peptide Cancer Vaccine Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.3 BrightPath Biotherapeutics
- 7.3.1 BrightPath Biotherapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.3.2 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
- 7.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.4 TapImmune
- 7.4.1 TapImmune Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.4.2 TapImmune Peptide Cancer Vaccine Product Portfolio
- 7.4.3 TapImmune Peptide Cancer Vaccine Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.5 Immatics
- 7.5.1 Immatics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.5.2 Immatics Peptide Cancer Vaccine Product Portfolio
- 7.5.3 Immatics Peptide Cancer Vaccine Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.6 Imugene
- 7.6.1 Imugene Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.6.2 Imugene Peptide Cancer Vaccine Product Portfolio
- 7.6.3 Imugene Peptide Cancer Vaccine Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.7 Sellas
- 7.7.1 Sellas Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.7.2 Sellas Peptide Cancer Vaccine Product Portfolio
- 7.7.3 Sellas Peptide Cancer Vaccine Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.8 Generex Biotechnology
- 7.8.1 Generex Biotechnology Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.8.2 Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
- 7.8.3 Generex Biotechnology Peptide Cancer Vaccine Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.9 VAXON Biotech
- 7.9.1 VAXON Biotech Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.9.2 VAXON Biotech Peptide Cancer Vaccine Product Portfolio
- 7.9.3 VAXON Biotech Peptide Cancer Vaccine Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.10 OncoTherapy Science
- 7.10.1 OncoTherapy Science Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.10.2 OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
- 7.10.3 OncoTherapy Science Peptide Cancer Vaccine Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.11 ISA Pharmaceuticals
- 7.11.1 ISA Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.11.2 ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
- 7.11.3 ISA Pharmaceuticals Peptide Cancer Vaccine Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 8 Industry Chain Analysis
- 8.1 Peptide Cancer Vaccine Industry Chain Analysis
- 8.2 Peptide Cancer Vaccine Industry Upstream Supply Analysis
- 8.2.1 Upstream Key Raw Material Supply Analysis
- 8.2.2 Raw Material Suppliers and Contact Information
- 8.3 Peptide Cancer Vaccine Product Downstream Application Analysis
- 8.3.1 Global Peptide Cancer Vaccine Revenue Market Size by Application: 2024 & 2025 & 2032
- 8.3.2 Global Peptide Cancer Vaccine Revenue and Forecast Analysis by Application (2020-2032)
- 8.3.3 Global Peptide Cancer Vaccine Sales and Forecast Analysis by Application (2020-2032)
- 8.4 Peptide Cancer Vaccine Typical Downstream Customers
- 8.5 Peptide Cancer Vaccine Sales Channel Analysis
- 9 Research Findings and Conclusion
- 10 Methodology and Data Source
- 10.1 Methodology/Research Approach
- 10.2 Research Scope
- 10.3 Benchmarks and Assumptions
- 10.4 Date Source
- 10.4.1 Primary Sources
- 10.4.2 Secondary Sources
- 10.5 Data Cross Validation
- 10.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
